15 completed. 15 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 15 |
| Phase 3 | 2 | Completed 2 |
Follow Chronic Renal Failure: new trials by email Literature Review of Chronic Renal Failure trials Research Report on Chronic Renal Failure
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Chronic Kidney Disease. Dapagliflozin 10mg Tab, Balcinrenone 50mg Capsule, Balcinrenone 100mg Capsule - Chronic Renal Failure, Mechanistic Effects of SGLT2 Inhibition and/ or MR Antagonism on Body Fluid and Electrolyte Homeostatis | Phase 2 | Completed | Klinikum Nürnberg | 103 | 2023-07-13 | 2026-04-27 |
| Effects of Photobiomodulation in Salivary Analysis of Chronic Renal Failure Patients Photobiomodulation, Placebo - Xerostomia, Chronic Renal Failure | Phase 2 | Completed | University of Nove de Julho | 44 | 2016-07-01 | 2018-08-29 |
| A Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration OPC-41061, Placebo - Chronic Renal Failure | Phase 2 | Completed | Otsuka Pharmaceutical Co., Ltd. | 124 | 2014-12-01 | 2019-10-22 |
| Open-label Dose-finding Trial of OPC-41061 in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis OPC-41061 - Chronic Renal Failure | Phase 2 | Completed | Otsuka Pharmaceutical Co., Ltd. | 20 | 2013-07-01 | 2016-01-01 |
| A Phase 2, Multi-center, Open-label, Dose-finding Trial to Investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of OPC-41061 in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration OPC-41061 - Chronic Renal Failure | Phase 2 | Completed | Otsuka Pharmaceutical Co., Ltd. | 26 | 2013-06-01 | 2018-08-24 |
| TRK-100STP Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis) TRK-100STP high dose, TRK-100STP low dose, Placebo - Chronic Renal Failure, Glomerular Disease | Phase 2 / Phase 3 | Completed | Toray Industries, Inc | 892 | 2010-03-01 | 2015-02-04 |
| Change From Baseline to Chronic Kidney Disease Patient Before and After Administration Drug Placebo, HD-003 (800mg/day), HD-003 (1600mg/day) - Chronic Renal Failure | Phase 2 | Completed | Hyundai Pharmaceutical Co., LTD. | 62 | 2010-01-01 | 2017-06-16 |
| Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease CTA018 Injection - Chronic Kidney Disease, Secondary Hyperparathyroidism | Phase 2 | Completed | OPKO IP Holdings II, Inc. | 41 | 2008-10-01 | 2014-11-06 |
| Safety & Efficacy of Peginesatide for Treatment of Anemia in Participants on Dialysis Not Receiving an ESA peginesatide, Epoetin Alfa - Anemia, Chronic Renal Failure | Phase 2 | Completed | Affymax | 114 | 2008-06-01 | 2012-06-29 |
| Pharmacodynamics and Non-Clinical Inferiority of Heparin Sodium (Cristália) Compared With the Product Liquemine (Roche) in Chronic Renal Failure Heparin sodic - Cristália, heparin - Liquemine (Roche) - Chronic Renal Failure | Phase 2 / Phase 3 | Completed | Azidus Brasil | 62 | 2007-09-01 | 2009-01-26 |
| Peginesatide for Maintenance Treatment of Anemia in Participants on Hemodialysis peginesatide - Anemia, Chronic Kidney Disease | Phase 2 | Completed | Affymax | 91 | 2006-12-01 | 2012-06-29 |
| Efficacy and Safety of Peginesatide (AF37702) in the Treatment of Anemia in Participants With Chronic Kidney Disease Peginesatide - Anemia, Chronic Kidney Disease | Phase 2 | Completed | Takeda | 22 | 2006-04-06 | 2019-03-14 |
| Safety, PD & PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease Patients peginesatide - Anemia, Chronic Kidney Disease | Phase 2 | Completed | Affymax | 139 | 2005-09-01 | 2012-12-21 |
| Peginesatide for Anemia in Chronic Hemodialysis Patients peginesatide - Anemia, Chronic Kidney Disease | Phase 2 | Completed | Affymax | 165 | 2005-07-01 | 2012-12-21 |
| Erythropoietin Therapy in Patients With Chronic Renal Failure: A Study of Time Dependent Activity r-HuEPO - Hemodialysis, Chronic Renal Failure | Phase 2 | Completed | Sunnybrook Health Sciences Centre | 46 | 1993-10-01 | 2008-09-01 |
Kidney Failure, Chronic (15) · Renal Insufficiency, Chronic (7) · Anemia (6) · Hyperparathyroidism (1) · Hyperparathyroidism, Secondary (1) · Kidney Diseases (1) · Nephrosclerosis (1) · Parathyroid Diseases (1) · Red-Cell Aplasia, Pure (1) · Renal Insufficiency (1) · Xerostomia (1)
Chronic Disease (15) · Disease Attributes (15) · Female Urogenital Diseases (15) · Female Urogenital Diseases and Pregnancy Complications (15) · Male Urogenital Diseases (15) · Pathologic Processes (15) · Pathological Conditions, Signs and Symptoms (15) · Urogenital Diseases (15) · Urologic Diseases (15) · Kidney Diseases (14) · Renal Insufficiency (14) · Renal Insufficiency, Chronic (8) · Hematologic Diseases (6) · Hemic and Lymphatic Diseases (6) · Endocrine System Diseases (1)
hematide (5) · peginesatide (5) · Tolvaptan (3) · Epoetin Alfa (1) · Erythropoietin (1) · Low-Level Light Therapy (1) · dapagliflozin (1)
Affymax (4) · Otsuka Pharmaceutical Co., Ltd. (3) · Azidus Brasil (1) · Hyundai Pharmaceutical Co., LTD. (1) · Klinikum Nürnberg (1) · OPKO IP Holdings II, Inc. (1) · Sunnybrook Health Sciences Centre (1) · Takeda (1) · Toray Industries, Inc (1) · University of Nove de Julho (1)
Japan (4) · United Kingdom (3) · France (2) · Germany (2) · United States (2) · Brazil (1) · Bulgaria (1) · Canada (1) · China (1) · Hong Kong (1) · Malaysia (1) · Poland (1) · Romania (1) · Russia (1) · South Korea (1)
Kyoji Imaoka, Mr (2) · Vice President, Clinical Development (2) · Adriana Marton, MD (1) · Georg Bjarnason, MD, FRCPC (1) · Joel Melnick, MD (1)
PMID 19890127, PMID 21940838, PMID 22935486, PMID 25233856, PMID 35224730
2005 (2)